Войти в систему Зарегистрироваться бесплатно

Génomic Vision SA Год IPO

Что обозначает Год IPO в Génomic Vision SA?

Год IPO Génomic Vision SA является 2014

Какое определение для Год IPO?

Первичное публичное размещение акций - это тип публичного предложения, при котором акции компании обычно продаются институциональным инвесторам, которые, в свою очередь, впервые продают эти акции широкой публике на фондовой бирже.

Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.

Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.

The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.

Год IPO компаний в Health Care сектор на EURONEXT по сравнению с Génomic Vision SA

Что делает Génomic Vision SA?

Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company offers FiberVision, a molecular combing platform that helps in DNA analysis workflow; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision, a scanner that acquires high resolution images of the whole surface of the coverslip with a hands-off workflow; FiberStudio, a software, which detects hybridization signals and analyzes data to generate results and reporting; FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. It also provides FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, the company offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. It has a strategic alliance with Quest Diagnostics; and development agreement with La Timone Hospital; research and development agreement with the Institut Pasteur. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.

Компании с год ipo похож на Génomic Vision SA